THE BIOTECH GROWTH TRUST PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 980 GBX | -1.80% |
|
-2.00% | +9.62% |
| Jun. 05 | Biotech Growth Trust sighs relief as sharply outperforms benchmark | AN |
| Jun. 05 | Biotech Growth beats benchmark | AN |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 381.4 | 319.1 | 593 | 369.6 | 303.3 | 333.2 |
| Enterprise Value (EV) 1 | 392.3 | 351.9 | 618.3 | 401.3 | 320.7 | 378.1 |
| P/E ratio | 18.9 x | 6.04 x | 2.85 x | -1.84 x | -7.64 x | 4.81 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.1 x | 4.63 x | 2.67 x | -1.8 x | -9.36 x | 4.15 x |
| EV / Revenue | 13.5 x | 5.1 x | 2.78 x | -1.96 x | -9.89 x | 4.71 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | 19.5 x | 12.2 x | 4.44 x | -2.87 x | -20.9 x | 14.5 x |
| FCF Yield | 5.12% | 8.22% | 22.5% | -34.9% | -4.78% | 6.89% |
| Price to Book | 0.93 x | 0.87 x | 0.99 x | 0.94 x | 0.92 x | 0.92 x |
| Nbr of stocks (in thousands) | 51,968 | 39,207 | 41,585 | 41,159 | 38,737 | 33,487 |
| Reference price 2 | 7.340 | 8.140 | 14.26 | 8.980 | 7.830 | 9.950 |
| Announcement Date | 5/24/19 | 6/12/20 | 6/17/21 | 6/1/22 | 6/14/23 | 6/6/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 29.04 | 68.94 | 222.1 | -204.9 | -32.42 | 80.35 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | 24.49 | 64.66 | 197.3 | -199.8 | -36.69 | 76.5 |
| Operating Margin | 84.31% | 93.79% | 88.85% | 97.47% | 113.18% | 95.21% |
| Earnings before Tax (EBT) 1 | 21.29 | 61.1 | 200.6 | -202.3 | -41.24 | 74.76 |
| Net income 1 | 21.1 | 60.9 | 200.4 | -202.4 | -41.3 | 74.6 |
| Net margin | 72.65% | 88.34% | 90.24% | 98.77% | 127.4% | 92.85% |
| EPS 2 | 0.3877 | 1.349 | 5.005 | -4.884 | -1.025 | 2.070 |
| Free Cash Flow 1 | 20.09 | 28.94 | 139.4 | -140 | -15.34 | 26.07 |
| FCF margin | 69.19% | 41.98% | 62.76% | 68.33% | 47.31% | 32.45% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | 95.23% | 47.52% | 69.55% | - | - | 34.95% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/24/19 | 6/12/20 | 6/17/21 | 6/1/22 | 6/14/23 | 6/6/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 10.8 | 32.7 | 25.3 | 31.7 | 17.4 | 44.9 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 20.1 | 28.9 | 139 | -140 | -15.3 | 26.1 |
| ROE (net income / shareholders' equity) | 5.11% | 15.7% | 41.5% | -40.7% | -11.4% | 21.6% |
| ROA (Net income/ Total Assets) | 3.49% | 9.71% | 23.5% | -23.2% | -5.82% | 12.4% |
| Assets 1 | 604.8 | 627.2 | 853.7 | 873.1 | 709.5 | 602.2 |
| Book Value Per Share 2 | 7.870 | 9.320 | 14.50 | 9.580 | 8.530 | 10.80 |
| Cash Flow per Share | - | - | 0.0400 | - | 0.0700 | 0.0600 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/24/19 | 6/12/20 | 6/17/21 | 6/1/22 | 6/14/23 | 6/6/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.8
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +9.62% | 416M | |
| +10.15% | 14.84B | |
| +4.37% | 6.34B | |
| +27.17% | 4.95B | |
| +8.09% | 4.29B | |
| -12.41% | 3.8B | |
| +14.71% | 3.48B | |
| -1.91% | 3.32B | |
| +9.79% | 3.07B | |
| +10.36% | 2.78B |
- Stock Market
- Equities
- BIOG Stock
- Financials The Biotech Growth Trust PLC
